ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 0593

Labour Force Participation Among Individuals with Osteoarthritis, Rheumatoid Arthritis/Other Arthritis Types, or with Joint Symptoms but Without a Diagnosis: An Age-Stratified Population-Based Study
Abstract Number: 0872

Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1086

Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Abstract Number: 0017

Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
Abstract Number: 0520

Leukocyte Immunoglobulin-like Receptor A3 Facilitates Neutrophil Extracellular Trap Formation in TLR7-induced Lupus Mice
Abstract Number: PP02

Leveraging Digital Health Tracking to Improve Arthritis Management
Abstract Number: 0060

Lipidomic Profiling Identifies Different Expression of Oxylipins Between Synovial Tissue and Plasma of Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 0327

Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Abstract Number: 1482

LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Abstract Number: 1480

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis
Abstract Number: 0822

Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Abstract Number: 0552

Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis
Abstract Number: 1475

Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants
Abstract Number: 1627

Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
Abstract Number: 1641

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review
Abstract Number: 1447

Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
Abstract Number: 1443

Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
Abstract Number: 1692

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: 3-year Results from the SELECT-EARLY Study
Abstract Number: 0781

Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Abstract Number: 1760

Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
Abstract Number: 0410

Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019
Abstract Number: 0245

Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Abstract Number: 1345

Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study
Abstract Number: 0913

Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
Abstract Number: 0828

Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
Abstract Number: 1337

Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Abstract Number: 1709

Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
Abstract Number: 0190

Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry
Abstract Number: 1803

Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
Abstract Number: 1691

Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Abstract Number: 0347

Longitudinal ANA Titers in SLE and ANA+ Controls
Abstract Number: 1281

Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures
Abstract Number: 1502

Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
Abstract Number: 0971

Longitudinal CyTOF Immunophenotyping Reveals Distinct Patterns of T cell-B Cell Dysregulation in SLE
Abstract Number: 0418

Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
Abstract Number: 1299

Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
Abstract Number: 0504

Longitudinal Patterns of Vascular Inflammation in Large-vessel Vasculitis
Abstract Number: 1469

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries
Abstract Number: 0941

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA
Abstract Number: 0969

Loss of Balance Between Protective and Pro-inflammatory Synovial Tissue T Cell Polyfunctionality Predates Clinical Onset of Rheumatoid Arthritis
Abstract Number: 0302

Loss of TAM Receptor Mer Contributes to Sjögren’s Syndrome–like Disease in Mice
Abstract Number: 0014

Low Baseline Expression of Pyruvate Kinase and Succinate Dehydrogenase Genes in the Peripheral Blood of Rheumatoid Arthritis Patients Treated with Tofacitinib Is Associated with Clinical Remission at the End of Follow-up
Abstract Number: 1224

Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab
Abstract Number: 0901

Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
Abstract Number: 1535

Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Abstract Number: 1342

Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year
Abstract Number: 1238

Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 1805

Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis
Abstract Number: 1553

Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
Abstract Number: 1693

Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Abstract Number: 1404

Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study
Abstract Number: 0709

Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis
Abstract Number: 0990

Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Abstract Number: 0808

Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
Abstract Number: 1453

Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Abstract Number: 0865

Lupus Low Disease Activity State Attainment Provides Significant Protection Against Mortality: A Multi-National, Longitudinal Observational Study
Abstract Number: 0595

Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Abstract Number: 0454

Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Abstract Number: 1460

Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Abstract Number: 0534

Lymphatic Dysfunction in Murine Lupus Photosensitivity
Abstract Number: 0309

Lymphopenia and Leukopenia in Sjogren Syndrome

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].